Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential-Reference-Cited by-同舟云学术

Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential

Published:2009-10-27 Issue:1 Volume:11 Page:75-77
ISSN:1470-3203
Container-title:Journal of the Renin-Angiotensin-Aldosterone System
language:en
Short-container-title:J Renin Angiotensin Aldosterone Syst

Author:

Unger Thomas¹,Dahlöf Björn²

Affiliation:

1. Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité - University Medicine Berlin, Germany,

2. Sahlgrenska University Hospital/Östra, University of Gothenburg, Sweden

Publisher

Hindawi Limited

Subject

Endocrinology,Internal Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1470320309347792

Reference20 articles.

1. The AT2 receptor—A matter of love and hate

2. Björn Fokow Award Lecture The angiotensin type 2 receptor

3. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice

4. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of novel indole-3-carboxylic acid derivatives with antihypertensive activity;Bioorganic & Medicinal Chemistry Letters;2023-06

2. A review of literature on Compound 21-loaded gelatin nanoparticle: a promising nose-to-brain therapy for multi-infarct dementia;The Egyptian Journal of Neurology, Psychiatry and Neurosurgery;2023-01-26

3. Manifestation of renin angiotensin system modulation in traumatic brain injury;Metabolic Brain Disease;2021-04-09

4. Angiotensin II;Handbook of Hormones;2021

5. The Brain AT2R—a Potential Target for Therapy in Alzheimer’s Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics;Molecular Neurobiology;2020-06-12